iBio, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2019, compared with fiscal year ended June 30, 2018. The requested “2018 Q4” period does not match this filing, which is an annual report for fiscal 2019.
Business Context
iBio is a plant-based biologics development and manufacturing company. Its FastPharming platform supports process development, cGMP manufacturing, aseptic fill/finish, bioanalytics, regulatory support, facility design, technology transfer and development of proprietary therapeutics. The company’s lead internal candidate is IBIO-CFB03 for fibrotic diseases, including systemic sclerosis and idiopathic pulmonary fibrosis; no company product had been commercialized or approved.
iBio owns 99.99% of iBio CDMO, which operates a 139,000-square-foot facility in Bryan, Texas under a 34-year capital lease from an Eastern Capital affiliate. The facility is designed for large-scale plant-based biologics production.
Key Financial Metrics
| Metric | FY2019 | FY2018 | Change |
|---|---|---|---|
| Revenue | $2.018 million | $0.444 million | +$1.574 million |
| Operating loss | $15.788 million | $14.227 million | Worsened by $1.561 million |
| Net loss | $17.597 million | $16.108 million | Worsened by $1.489 million |
| Net loss attributable to iBio | $17.593 million | $16.105 million | Worsened by $1.488 million |
| Net loss available to common stockholders | $17.853 million | $16.365 million | Worsened by $1.488 million |
| Loss per share | $0.94 | $1.54 | Improved due primarily to increased share count |
| Research and development expense | $5.474 million | $3.986 million | +$1.488 million |
| General and administrative expense | $12.332 million | $10.685 million | +$1.647 million |
| Interest expense | $1.900 million | $1.915 million | -$0.015 million |
| Cash used in operating activities | $13.975 million | $13.480 million | Higher use of $0.495 million |
| Cash used in investing activities | $0.990 million | $1.079 million | Lower use of $0.089 million |
| Cash provided by financing activities | $3.453 million | $22.406 million | -$18.953 million |
| Cash balance | $4.421 million | $15.934 million | -$11.513 million |
| Accumulated deficit | $105.821 million | $88.228 million | Increased by $17.593 million |
| Stockholders’ equity | $2.463 million | $16.166 million | -$13.703 million |
Revenue increased primarily because of the CC-Pharming strategic relationship; CC-Pharming generated approximately $1.8 million, or about 92% of total fiscal 2019 revenue. Contract liabilities were $1.279 million at June 30, 2019, compared with none in the prior year, reflecting customer prepayments for services not yet performed.
Gross margin and net debt metrics are not separately presented in the provided filing text. The company had a capital lease obligation of $24.884 million, including $0.213 million current and $24.671 million long term. The lease carries annual base rent of approximately $2.1 million, subject to CPI adjustments, plus percentage rent and minimum sales-based rent provisions.
Material Changes Versus Prior Period
- Revenue grew approximately 355%, but remained substantially below operating expenses.
- R&D expense increased 37%, driven by higher personnel costs and third-party costs associated with the CC-Pharming project.
- G&A expense increased 15%, primarily due to facility maintenance, repairs, percentage rent, consulting and recruiting costs.
- Cash declined from $15.9 million to $4.4 million, while operating cash use increased to approximately $14.0 million.
- Fiscal 2019 financing included $1.35 million of over-allotment proceeds, a $2.459 million capital contribution from an Eastern affiliate and $0.197 million of capital lease payments.
- Series A preferred stock conversions increased common shares outstanding; 2,223 Series A preferred shares converted into 2.47 million common shares during fiscal 2019.
- The company completed a one-time stock option exchange, issuing 874,310 replacement options for 1,165,750 existing options. It also adopted the 2018 Omnibus Equity Incentive Plan.
- In March 2019, iBio entered a non-exclusive license agreement with the University of Natural Resources and Life Sciences, Vienna, concerning modified N-glycosylation plant materials.
- The Delaware Chancery Court dismissed iBio’s separate complaint against Fraunhofer-Gesellschaft as untimely; the action against Fraunhofer USA remained pending.
Liquidity, Outlook and Risks
Management stated that the $4.4 million cash balance at June 30, 2019 was expected to fund operations only through approximately September 30, 2019. The company was seeking additional financing and had engaged an investment banking firm. Potential funding sources included additional equity or other securities, licensing and collaboration proceeds, and CDMO revenue.
The auditor’s report and management disclosures identified substantial doubt about the company’s ability to continue as a going concern. iBio expects continued operating losses and significant expenses, particularly if it advances clinical programs or expands its CDMO operations. The filing does not provide a formal revenue, earnings or profitability guidance range.
- Financing may be unavailable or unfavorable, and future equity issuance could materially dilute existing stockholders.
- The company’s revenue base is highly concentrated in CC-Pharming and depends on continued customer spending and execution of collaborative projects.
- Underutilization of the Bryan facility could pressure margins and liquidity, while minimum rent provisions could require payments even if sales are below thresholds.
- The company has not obtained regulatory approval for any proprietary therapeutic or vaccine candidate, and most candidates remain in preclinical development.
- Clinical development, regulatory approval, manufacturing quality, intellectual property protection and customer retention remain significant uncertainties.
- Stockholders’ equity was $2.5 million, below the NYSE American $6 million standard cited in the filing. The company expected to regain or maintain compliance through additional financing, but acknowledged that success was uncertain.
- The company remains involved in litigation with Fraunhofer regarding alleged contractual breaches, technology transfer and intellectual property rights; the outcome and potential financial effect were not predictable.
Most Important Facts to Verify
- Whether the company obtained sufficient financing after September 30, 2019 to address the going-concern uncertainty.
- Actual cash burn, revenue collections and contract liability recognition following fiscal year-end.
- Whether CC-Pharming generated additional work, payments or material revenue beyond fiscal 2019.
- The status and terms of any subsequent equity, preferred-stock conversion or other financing transactions, including dilution.
- Current compliance with NYSE American stockholders’ equity and minimum share-price requirements.
- The status, economics and expected timing of IBIO-CFB03’s IND development and any regulatory interactions.
- The outcome and financial consequences of the remaining Fraunhofer litigation.
- Actual utilization, customer pipeline and profitability prospects of the Bryan CDMO facility.